一种超分子光敏剂及其制备方法和应用
By co-assembling photosensitizers with electron acceptors to form supramolecular photosensitizers, the problem of strong oxygen dependence of type II photosensitizers has been solved, achieving highly efficient tumor cell killing in hypoxic environments and promoting the development of type I photodynamic therapy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING NORMAL UNIVERSITY
- Filing Date
- 2022-05-18
- Publication Date
- 2026-07-17
AI Technical Summary
In current photodynamic therapy, type II photosensitizers are highly dependent on oxygen concentration, and the hypoxic tumor microenvironment limits their efficacy. The lack of effective design strategies for type I photosensitizers has restricted the development of type I photodynamic therapy.
A supramolecular photosensitizer is formed by co-assembling photosensitizer and electron acceptor through quadruple hydrogen bonding, which promotes electron transfer to generate superoxide radicals, oxidizes NADH, and kills cancer cells. It is suitable for both normal oxygen concentration and hypoxic conditions.
It can effectively inhibit tumor cells under both normal oxygen concentration and hypoxic conditions, enhance the efficacy of photodynamic therapy, and broaden the design ideas of type I photodynamic therapy.
Smart Images
Figure CN117126184B_ABST